179 related articles for article (PubMed ID: 27581780)
21. Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.
Marcos-Zambrano LJ; Puig-Asensio M; Pérez-García F; Escribano P; Sánchez-Carrillo C; Zaragoza O; Padilla B; Cuenca-Estrella M; Almirante B; Martín-Gómez MT; Muñoz P; Bouza E; Guinea J
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438935
[TBL] [Abstract][Full Text] [Related]
22. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
23. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
24. Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.
Nishida R; Eriguchi Y; Miyake N; Nagasaki Y; Yonekawa A; Mori Y; Kato K; Akashi K; Shimono N
Med Mycol; 2023 Jun; 61(6):. PubMed ID: 37312399
[TBL] [Abstract][Full Text] [Related]
25. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
26. Occurrence, presentation and treatment of candidemia.
Mikulska M; Del Bono V; Ratto S; Viscoli C
Expert Rev Clin Immunol; 2012 Nov; 8(8):755-65. PubMed ID: 23167687
[TBL] [Abstract][Full Text] [Related]
27. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients.
Muro MD; Motta Fde A; Burger M; Melo AS; Dalla-Costa LM
J Clin Microbiol; 2012 Nov; 50(11):3783-5. PubMed ID: 22895037
[TBL] [Abstract][Full Text] [Related]
28. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
Chen YC; Kuo SF; Chen FJ; Lee CH
Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility and molecular characterization of Candida spp. from candidemic patients.
Herkert PF; Gomes RR; Muro MD; Pinheiro RL; Fornari G; Vicente VA; Queiroz-Telles F
Rev Iberoam Micol; 2015; 32(4):221-8. PubMed ID: 25681153
[TBL] [Abstract][Full Text] [Related]
31. [Emergence of Candida parapsilosis candidemia at Cochin hospital. Characterization of isolates and search for risk factors].
Paugam A; Baixench MT; Taieb F; Champagnac C; Dupouy-Camet J
Pathol Biol (Paris); 2011 Feb; 59(1):44-7. PubMed ID: 20889268
[TBL] [Abstract][Full Text] [Related]
32. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
[TBL] [Abstract][Full Text] [Related]
33. Post-mortem analysis of Candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient.
Chrenkova V; Hubacek P; Sedlacek P; Riha P; Kodetová D; Bébrová E
Epidemiol Mikrobiol Imunol; 2014 Jun; 63(2):121-4. PubMed ID: 25025677
[TBL] [Abstract][Full Text] [Related]
34. Candidemia and invasive candidiasis in adults: A narrative review.
Antinori S; Milazzo L; Sollima S; Galli M; Corbellino M
Eur J Intern Med; 2016 Oct; 34():21-28. PubMed ID: 27394927
[TBL] [Abstract][Full Text] [Related]
35. Our 2014 approach to candidaemia.
Koehler P; Tacke D; Cornely OA
Mycoses; 2014 Oct; 57(10):581-3. PubMed ID: 24863378
[TBL] [Abstract][Full Text] [Related]
36. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
37. Candida orthopsilosis fungemias in a Spanish tertiary care hospital: incidence, epidemiology and antifungal susceptibility.
Blanco-Blanco MT; Gómez-García AC; Hurtado C; Galán-Ladero MA; Lozano Mdel C; García-Tapias A; Blanco MT
Rev Iberoam Micol; 2014; 31(2):145-8. PubMed ID: 23680638
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of candidemia caused by Candida albicans and Candida non - albicans in patients with hematological malignancies].
Klyasova GA; Malchikova AO; Tandilova KS; Blohina EV; Parovichnikova EN; Kravchenko SK; Savchenko VG
Ter Arkh; 2019 Aug; 91(8):84-92. PubMed ID: 32598758
[TBL] [Abstract][Full Text] [Related]
39. Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
Conen A; Weisser M; Jörg CO; Battegay M; Trampuz A; Frei R; Christen S; Heim D; Gratwohl A; Flückiger U
Transpl Infect Dis; 2008 Feb; 10(1):66-70. PubMed ID: 17511816
[TBL] [Abstract][Full Text] [Related]
40. Candida norvegensis fungemia in a liver transplant recipient.
Sanclemente G; Marco F; Cervera C; Hoyo I; Colmenero J; Pitart C; Almela M; Navasa M; Moreno A
Rev Iberoam Micol; 2015; 32(2):115-7. PubMed ID: 24794213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
